Slingshot Insights | Pfe Overview

PFE Overview

Upcoming Projects (PFE)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (PFE)

Reviewing the recent decision by Pfizer to remove OXBRYTA (voxelotor) for sickle cell disease from the market.
Tickers: PFE, FULC
Executed On: Nov 12, 2024 at 04:45 PM EST
Discussing the treatment landscape for ROS1 NSCLC and the potential of taletrectinib
Tickers: NUVB, NUVL, BMY, PFE
Executed On: Sep 24, 2024 at 11:00 AM EDT
A second look: Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 18, 2024 at 04:00 PM EDT
Discussing the treatment landscape for cervical cancer
Tickers: MRK, PFE
Executed On: Sep 10, 2024 at 12:00 PM EDT
Discussing the potential of Vaxcyte's VAX-31 and VAX-24, pneumococcal conjugate vaccine (PCV) candidates designed to prevent invasive pneumococcal disease (IPD)
Tickers: PCVX, MRK, PFE
Executed On: Sep 05, 2024 at 03:30 PM EDT
Looking at the FDA Approval of the Neffy Spray (intranasal ephinephrine) from ARS Pharmaceuticals for anaphylactic shock
Tickers: SPRY, PFE, AQST
Executed On: Aug 15, 2024 at 04:45 PM EDT
A Second Look: Discussing the role of the PRC2/EZH2/EED pathway in prostate cancer
Tickers: ORIC, EPIX, PFE
Executed On: Jul 26, 2024 at 12:30 PM EDT
Discussing the role of the PRC2/EZH2/EED pathway in prostate cancer
Tickers: ORIC, EPIX, PFE
Executed On: Jul 12, 2024 at 10:00 AM EDT
Discussing highlights from ESMO in breast cancer: Pfizer's CDK4-selective inhibitor PF-07220060, Arvinas/Pfizer Vepdegestrant/palbociclib combo & Olema's palazestrant/ribociclib combo
Tickers: PFE, ARVN, OLMA
Executed On: Jun 10, 2024 at 09:00 AM EDT
Discussing new therapies for the treatment of sickle cell disease with a hematologist.
Tickers: AGIO, PFE
Executed On: Apr 02, 2024 at 10:00 AM EDT
A Second Look: A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 13, 2023 at 03:00 PM EST
A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 10, 2023 at 04:00 PM EST
An updated look at the results from the ATTRibute-CM trial of Acoramidis in patients with transthyretin amyloid cardiomyopathy
Tickers: BBIO, PFE, ALNY
Executed On: Sep 06, 2023 at 10:30 AM EDT
A Second Look: Discussing the FDA approval of the Revi System, a tibial nerve stimulation system developed by BlueWind Medical for overactive bladder
Tickers: BLUEWIND MEDICAL, ALPMY, MDT, PFE
Executed On: Aug 25, 2023 at 04:00 PM EDT
Discussing the FDA approval of the Revi System, a tibial nerve stimulation system developed by BlueWind Medical for overactive bladder
Tickers: BLUEWIND MEDICAL, MDT, PFE, ALPMF
Executed On: Aug 24, 2023 at 09:00 AM EDT
Discussing the ATTRibute Part B results on Acoramidis for patients with ATTR cardiomyopathy.
Tickers: BBIO, PFE, ALNY
Executed On: Jul 20, 2023 at 09:00 AM EDT
A Third View: Discussing acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 12, 2023 at 01:00 PM EDT
A Second View: A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 11, 2023 at 01:30 PM EDT
A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Tickers: BBIO, PFE, ALNY
Executed On: Jul 07, 2023 at 01:00 PM EDT
A Second Opinion: Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker: PFE
Executed On: Jun 20, 2023 at 07:00 PM EDT
Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker: PFE
Executed On: Jun 14, 2023 at 02:00 PM EDT
Discussing private and commercial payer reimbursement strategies in the US for Pfizer's Paxlovid with a billing expert who interacts with pharmaceutical companies related to COVID-19 treatment.
Ticker: PFE
Executed On: Apr 21, 2023 at 04:00 PM EDT
Discussing the treatment landscape for alopecia areata with a focus on therapies from Incyte, Concert, Lilly, Pfizer, and Equillium
Tickers: INCY, CNCE, LLY, EQ, PFE
Executed On: Mar 08, 2023 at 01:30 PM EST
An overview of next generation "oral biologics" in treating inflammatory/rheumatological disease
Tickers: IBB, ACRS, DICE, VTYX, IMUX, KYMR, BMY, PTGX, PFE
Executed On: Dec 08, 2022 at 04:00 PM EST
Examining the potential of Valneva and Pfizer's Lyme disease vaccine, VLA15
Tickers: VALN, PFE
Executed On: Nov 01, 2022 at 01:00 PM EDT
Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002
Tickers: BMY, PFE, CNTB, VTYX
Executed On: Sep 23, 2022 at 02:00 PM EDT
Examining the use of Nurtech in migraines and where AXS-07 could fit in if approved
Tickers: AXSM, BHVN, PFE
Executed On: Jul 22, 2022 at 11:00 AM EDT
A look into the proposed mRNA-based vaccine for the prevention of Shingles
Tickers: BNTX, PFE
Executed On: May 24, 2022 at 02:00 PM EDT
A look into the current and developing S1P1 modulators as treatment for Ulcerative Colitis
Tickers: PFE, BMY, CNTB, VTYX
Executed On: Apr 22, 2022 at 01:00 PM EDT
A Second Look: Discussing the potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 24, 2022 at 12:00 PM EST
A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 01:00 PM EST
A Second View: Discussing the Pneumococcal vaccine market and where a new vaccine could potentially fit in
Tickers: PFE, PCVX, GSK, MRK, Affinivax, ALPMY
Executed On: Jan 07, 2022 at 10:00 AM EST

Expired Projects (PFE)

Test
Ticker: PFE
Execute By: Oct 10, 2024
Discussing Pfizer’s respiratory syncytial virus vaccine, Abrysvo
Ticker: PFE
Execute By: May 31, 2023
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022
Exploring the recent hemophilia A - SB-525 gene therapy data from Sangamo
Tickers: SGMO, PFE
Execute By: Aug 30, 2019
Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29th
Tickers: ARIA, TKPYY, PFE, NVS, RHHBY, Genentech
Execute By: Apr 28, 2017
Discussing the Effectiveness and Market Potential of Pfizer's (PFE) Crisaborole in Atopic Dermatitis After January 7th PDUFA Date
Ticker: PFE
Execute By: Feb 01, 2017
Electroporation Expert Interview: An Overview and its Pharmaceutical Potential
Tickers: INO, PFE, RHHBY, ROLL
Execute By: Nov 02, 2016
Included with Membership

Upcoming & Overdue Catalysts (PFE)

ARV-471 Phase 3 trial
Tickers: ARVN, PFE, OLMA
Future Window: Oct 01, 2023 - Dec 31, 2024

Occurred Catalysts (PFE)

Arvinas (ARVN) & Pfizer (PFE) announce update on Phase 1 dose escalation data of ARV-471 in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Tickers: ARVN, PFE
Occurred on: Dec 10, 2021
Pfizer/BioNTech's BNT162b2 vaccine against SARS-CoV-2 U.S. EUA application expected this month
Tickers: PFE, BNTX
Occurred on: Nov 20, 2020
Interim Analysis Results from Pfizer's (PFE) Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer
Ticker: PFE
Occurred on: Sep 30, 2019
Pfizer's (PFE) Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
Ticker: PFE
Occurred on: Aug 27, 2018
U.S. FDA Approves Pfizer’s (PFE) Biosimilar NIVESTYM (filgrastim-aafi)
Ticker: PFE
Occurred on: Jul 18, 2018
Pfizer (PFE) And Lilly (LLY) Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab at 16-weeks For The Treatment Of Osteoarthritis (OA) Pain
Tickers: PFE, LLY
Occurred on: Jul 18, 2018
Pfizer (PFE) initiates a Phase 3 open-label lead-in study evaluating current factor IX prophylaxis replacement therapy in the usual care setting for patients with hemophilia B
Ticker: PFE
Occurred on: Jul 16, 2018
Advisory Committee Meeting for Pfizer's(PFE) Staphylococcus aureus vaccine for pre-surgical prophylaxis expected November 7 2017
Ticker: PFE
Occurred on: Nov 07, 2017
U.S Department of Justice Issues Grand Jury Subpoenas to Pfizer (PFE), ICUI, & BAX as Part of an Antitrust Investigation into the IV Saline Solution Market
Tickers: PFE, BAX, ICUI
Occurred on: Apr 19, 2017
PDUFA Date of April 2017 for Pfizer's (PFE) Supplemental New Drug Application (sNDA) for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Ticker: PFE
Occurred on: Apr 03, 2017
Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Present New Analyses of Eliquis (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session taking place March 17-19
Tickers: BMY, PFE
Occurred on: Mar 17, 2017
Pfizer's' (PFE) Xeljanz Approved in China for Treatment of Adults With Moderate-to-Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response or are Intolerant of Methotrexate (MTX)
Ticker: PFE
Occurred on: Mar 15, 2017
Pfizer (PFE) Launches Zavicefta in the UK and Germany as a Combination Antibiotic to Treat Gram-Negative Bacterial Infections Requiring Hospitalization
Ticker: PFE
Occurred on: Mar 14, 2017
Merck (MRK) and Pfizer (PFE) Plan to Submit NDA By End of 2016 for Ertugliflozin in Combination with Januvia (sitagliptin) and Metformin in Treatment of Type 2 Diabetes
Tickers: MRK, PFE
Occurred on: Mar 06, 2017
European Commission (EC) Approves Roche's (RHHBY) Alecensa for Adult Patients with Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer Who Have Taken Pfizer's (PFE) Xalkori (Crizotinib)
Tickers: RHHBY, PFE
Occurred on: Feb 21, 2017
Pfizer (PFE) Presents Phase 3b/4 ORAL Strategy Data Evaluating XELJANZ + Methotrexate (MTX) Compared to AbbVie's (ABBV) Humira in Moderate-to-Severe Rheumatoid Arthritis (RA)
Ticker: PFE
Occurred on: Feb 16, 2017
Pfizer (PFE) AnnouncesTop-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection
Ticker: PFE
Occurred on: Jan 26, 2017
Pfizer's (PFE) Supplemental New Drug Application for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (ER+, HER2-) Metastatic Breast Cancer Accepted for FDA Review
Ticker: PFE
Occurred on: Dec 21, 2016
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016
PDUFA Date of January 7, 2017 for Pfizer's (PFE) Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis
Ticker: PFE
Occurred on: Dec 14, 2016
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Ticker: PFE
Occurred on: Nov 29, 2016
PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
Ticker: PFE
Occurred on: Nov 16, 2016
Pfizer (PFE) Expects Decision From European Medicines Agency on IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer By End of November
Ticker: PFE
Occurred on: Nov 10, 2016
Pfizer's (PFE) Prevenar Approved in China for the Prevention of Invasive Pneumococcal Disease in Infants and Children Aged Six Weeks to Fifteen Months
Ticker: PFE
Occurred on: Nov 02, 2016
Pfizer (PFE) Terminates Development of Cholesterol Lowering Candidate Bococizumab
Ticker: PFE
Occurred on: Nov 01, 2016
Esperion Therapeutics (ESPR) Announces Phase 2 Data Evaluating Bempedoic Acid Added to Atorvastatin in Hypercholesterolemia
Tickers: ESPR, PFE
Occurred on: Oct 13, 2016
Pfizer (PFE) Presents Phase 3 S-TRAC Results Evaluating Sutent (sunitinib) in Patients with Renal Cell Carcinoma
Ticker: PFE
Occurred on: Oct 10, 2016
2nd Presidential Debate between Donald Trump and Hillary Clinton at Washington University in St. Louis, Missouri from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, MYL, Turing Pharmaceuticals, GILD
Occurred on: Oct 09, 2016
First Presidential debate between Donald Trump and Hillary Clinton at Hofstra University, New York, from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, GILD, MYL
Occurred on: Sep 26, 2016
Pfizer (PFE) Announces Phase 3 REFLECTIONS B537-02 Data Evaluating Remicade Biosimilar in Rheumatoid Arthritis
Tickers: PFE, NVS
Occurred on: Sep 16, 2016
Pfizer's (PFE) IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer Recommended for Approval by European Ad Comm
Ticker: PFE
Occurred on: Sep 16, 2016
Merck (MRK) and Pfizer (PFE) Announce Phase 3 Results for Type 2 Diabetes Candidate Ertugliflozin
Tickers: MRK, PFE
Occurred on: Sep 15, 2016
Aerie Pharmaceuticals (AERI) Releases Positive Phase 3 Data on Roclatan for Lowering Intraocular Pressure (IOP) in Patients with Glaucoma or Ocular Hypertension
Tickers: AERI, PFE
Occurred on: Sep 14, 2016
FDA Approves TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
Ticker: PFE
Occurred on: Aug 19, 2016
Pfizer reaches $486M settlement of nationwide litigation relating to its Celebrex and Bextra pain-relieving drugs of Celebrex, Bextra pain-relieving drugs
Ticker: PFE
Occurred on: Aug 02, 2016
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
Ticker: PFE
Occurred on: Jul 13, 2016
Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49
Ticker: PFE
Occurred on: Jul 12, 2016
BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer
Tickers: BIND, PFE
Occurred on: Jul 01, 2016
Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia
Ticker: PFE
Occurred on: Jun 12, 2016
Merck And Pfizer Announce Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes
Tickers: PFE, MRK
Occurred on: Jun 11, 2016
Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis
Ticker: PFE
Occurred on: Jun 07, 2016
The First Phase 3 trial for Plecanatide in IBS-C read out
Tickers: SGYP, PFE, AGN, VRX, IRWD
Occurred on: May 22, 2016
Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold
Tickers: PFE, LLY
Occurred on: Mar 23, 2016
Pfizer Announces FDA Approval of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
Ticker: PFE
Occurred on: Feb 24, 2016
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
GlycoMimetics (GLYC) and Pfizer (PFE) Initiate Phase 1 Trial Evaluating Subcutaneous Administration of Rivipansel in Vaso-Occlusive Crisis in Sickle Cell Disease
Tickers: GLYC, PFE
Occurred on: Oct 29, 2015
Allergan (AGN) Launches Over-the-counter Artificial Tear REFRESH OPTIVE Gel Drops for Dry Eye Symptoms
Tickers: AGN, PFE
Occurred on: Oct 21, 2015
Allergan (AGN) Issues Statement Regarding Specialty Pharmacy Utilization and Resumes Trading
Tickers: AGN, PFE, VRX
Occurred on: Oct 21, 2015
Allergan (AGN) Completes Acquisition of AqueSys and XEN45 for $300 Million
Tickers: AGN, PFE
Occurred on: Oct 19, 2015
FDA Grants Pfizer's (PFE) Inotuzumab Ozogamicin Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia
Ticker: PFE
Occurred on: Oct 19, 2015
Allergan (AGN) Presents Data From Harmony Study on Combined Facial Aesthetic Treatment With Botox, Dermal Fillers, and Bimatoprost
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Allergan (AGN) Presents Paper Titled "Facial Treatment Preferences in Aesthetically-Oriented Men" at American Society of Dermatologic Surgery Meeting
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
FDA Sends Pfizer (PFE) Complete Response Letter Rejecting Oral XELJANZ Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis
Ticker: PFE
Occurred on: Oct 14, 2015

Strategic Initiatives (PFE)

Myovant Sciences (MYOV) and Pfizer (PFE) Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Tickers: MYOV, PFE
Announcement Date: Dec 28, 2020
Pfizer (PFE) spin off Upjohn Business merges with Mylan N.V. (MYL), forming Viatris Inc. (VTRS)
Tickers: PFE, MYL
Announcement Date: Nov 16, 2020
Pfizer (PFE) is set to purchase 5,000,000 of Homology’s (FIXX) common stock at a price of $12.00 per share
Tickers: FIXX, PFE
Announcement Date: Nov 09, 2020
Antares Pharma (ATRS) Enters into a Development Agreement with Pfizer (PFE) to develop a combination drug device rescue pen
Tickers: ATRS, PFE
Announcement Date: Aug 06, 2018
ICU Medical (ICUI) Announces $1B Cash & Stock Purchase of Pfizer's (PFE) Hospira Infusion Therapy Unit
Tickers: ICUI, PFE
Announcement Date: Oct 06, 2016
Pfizer (PFE) Decides Not to Split Company, Will Operate as One Company With Two Distinct and Complementary Businesses to Maximize Future Value Creation
Ticker: PFE
Announcement Date: Sep 26, 2016
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Tickers: PFE, AZN
Announcement Date: Aug 24, 2016
Pfizer near $14 billion acquisition of Medivation
Tickers: PFE, MDVN
Announcement Date: Aug 21, 2016
BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets
Tickers: BIND, PFE
Announcement Date: Jul 26, 2016
Pfizer Completes Acquisition of Anacor
Tickers: PFE, ANAC
Announcement Date: Jun 23, 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016